Thymalin vs Pancragen
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Thymalin is a polypeptide complex isolated from calf thymus glands (developed by the Russian Gerontology Institute), shown to restore immune function, extend lifespan, and reverse thymic involution. Clinical studies demonstrate improved immune parameters and up to 40% reduction in mortality in elderly patients.
- Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
- Half-Life
- Not well characterized as a complex extract; individual peptides have varying kinetics
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- SubQ, IM
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 10 mg IM or SC daily
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Restores thymic function and T-cell immunity
- Extends healthy lifespan (documented in long-term studies)
- Reduces infectious disease incidence in elderly
- Normalizes immune parameters in immunodeficiency
- Anti-tumor immune surveillance
- Improves vaccine response in elderly
- Reduces cardiovascular mortality (40% in landmark Russian study)
- Normalizes neuroendocrine function
- Supports pancreatic beta cell function and insulin secretion
- May improve glucose metabolism in early metabolic dysfunction
- Protective effects on exocrine pancreatic tissue
- Anti-aging effects on pancreatic cells
- Potential support in type 2 diabetes management alongside standard care
- Reduces pancreatic cellular apoptosis from metabolic stress
- Complementary to GLP-1 agonists in metabolic protocols
- Side Effects
- Very well tolerated in decades of Russian clinical use
- Mild injection site reactions
- Rare: mild allergic reaction (natural extract)
- Transient flu-like symptoms on initiation (immune activation)
- Generally well tolerated
- Mild injection site reactions
- No significant hypoglycemic events reported at standard doses as monotherapy
- Stacks With
- —
- —